Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Next Previous
Trial Profile

Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asparaginase (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Idarubicin (Primary) ; Methotrexate (Primary) ; Folinic acid
  • Indications Blastic plasmacytoid dendritic cell neoplasm
  • Focus Therapeutic Use
  • Acronyms LpDessai

Most Recent Events

  • 07 Feb 2024 Planned End Date changed from 1 May 2025 to 1 Nov 2024.
  • 07 Feb 2024 Status changed from recruiting to active, no longer recruiting.
  • 31 May 2022 Planned End Date changed from 1 May 2022 to 1 May 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top